Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• MarketBeat consensus: "Moderate Buy" — nine analysts cover Bayer with a split of 2 sells, 5 buys and 2 strong buys, amid recent mixed rating changes from firms including UBS, Barclays, Zacks and DZ Bank.
• Q1 results and guidance: Bayer reported $0.18 EPS (in line) and $13.24B revenue (above expectations), has a negative net margin of 8.51% and ROE of 15.35%, and set FY2026 EPS guidance of 1.251–1.400 (consensus ~1.31).
• Stock and financial snapshot: Shares traded up ~1.7% at a $45B market cap, P/E of -10.32, 52-week range $5.30–$14.85, 50-/200-day averages $12.17/$10.37, and debt-to-equity ~1.10 with a current ratio of 1.14.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine ratings firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company.

Several research analysts recently issued reports on the stock. Zacks Research lowered shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong sell" rating in a research report on Tuesday, March 24th. UBS Group upgraded Bayer Aktiengesellschaft from a "neutral" rating to a "buy" rating in a research report on Monday, March 16th. Barclays upgraded Bayer Aktiengesellschaft from an "equal weight" rating to an "overweight" rating in a research report on Tuesday, January 6th. DZ Bank downgraded Bayer Aktiengesellschaft from a "strong-buy" rating to a "strong sell" rating in a research report on Wednesday, February 18th. Finally, JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a "neutral" rating to an "overweight" rating in a research report on Monday, December 8th.

Bayer Aktiengesellschaft Trading Up 1.7%

Bayer Aktiengesellschaft stock opened at $11.45 on Tuesday. The stock has a market cap of $45.00 billion, a P/E ratio of -10.32 and a beta of 0.70. Bayer Aktiengesellschaft has a fifty-two week low of $5.30 and a fifty-two week high of $14.85. The firm's fifty day moving average price is $12.17 and its 200-day moving average price is $10.37. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.71 and a current ratio of 1.14.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its quarterly earnings results on Wednesday, March 4th. The company reported $0.18 earnings per share for the quarter, hitting the consensus estimate of $0.18. The firm had revenue of $13.24 billion for the quarter, compared to analysts' expectations of $13.08 billion. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.35%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. Equities research analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women's health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.